Semaglutide Tablets: How Oral GLP-1 Medications Compare to Injections

*This article is for informational purposes only. It is not medical advice. Consult a licensed healthcare provider before starting any medication or making changes to your treatment plan.*

---

If you have been researching GLP-1 medications for weight management online, you have probably come across two things: weekly injections and, more recently, the emergence of semaglutide tablets online through telehealth platforms. Both options use the same active compound. Both work through the same mechanism. But they are meaningfully different in how they are absorbed, how convenient they are to use, and what you can expect from them in terms of results and side effects.

This guide explains what oral semaglutide is, how it compares to the injectable form, and what you should discuss with your provider when deciding between them.

---

What Is Oral Semaglutide?

Semaglutide is a GLP-1 receptor agonist: a medication that mimics a natural gut hormone involved in appetite regulation, blood sugar control, and slowing digestion. It was originally developed as an injectable, but researchers and pharmaceutical companies worked for years to create an oral version.

The challenge with oral delivery is that semaglutide is a peptide (a small protein), and proteins are normally broken down by stomach acid before reaching the bloodstream. To get around this, pharmaceutical manufacturers use a compound called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which briefly raises the pH of the stomach lining and allows semaglutide to be absorbed directly through the stomach wall.

The result is a pill that delivers semaglutide - though with important differences in how much of the dose actually enters your system.

FDA-approved oral semaglutide currently includes:

• Rybelsus (oral semaglutide 7mg and 14mg): Approved by the FDA in September 2019 for type 2 diabetes management - the first oral GLP-1 receptor agonist approved for that indication.
• Wegovy pill (oral semaglutide 25 mg): FDA-approved on December 22, 2025 as the first oral GLP-1 for chronic weight management, with the commercial launch beginning in early January 2026. This is a higher-dose formulation than the diabetes-approved Rybelsus.

Compounded oral semaglutide: Licensed compounding pharmacies may also prepare oral semaglutide formulations based on individual patient prescriptions from licensed providers. Compounded semaglutide tablets are not FDA-approved and are not the same product as Rybelsus or oral Wegovy. They are prepared specifically for each patient.

---

How Do GLP-1 Injections Work in Comparison?

Injectable semaglutide is administered subcutaneously (just under the skin), typically in the abdomen, thigh, or upper arm. Because it bypasses the digestive tract entirely, nearly 100% of the dose reaches the bloodstream.

The injectable form is given once weekly and reaches steady-state blood levels that are consistent and predictable. The dose is gradually increased over the first several months (a titration process) to reduce gastrointestinal side effects while the body adjusts.

FDA-approved injectable semaglutide for weight management:

• Wegovy (semaglutide 2.4mg injection): Approved in 2021 for chronic weight management in adults with obesity or overweight with a weight-related condition.
• Ozempic (semaglutide 0.5mg-2mg injection): Approved for type 2 diabetes; sometimes prescribed off-label for weight management.

Compounded injectable semaglutide: Available through licensed providers and compounding pharmacies. Not FDA-approved, not equivalent to Wegovy or Ozempic, and not subject to FDA review for safety, efficacy, or quality.

---

Oral vs Injectable Semaglutide: Key Differences

*Both tablet and injectable forms of semaglutide work by activating GLP-1 receptors, but they differ in absorption, dosing, and practical use.*

---

What the Research Shows

Injectable Semaglutide for Weight Loss

The STEP 1 clinical trial, published in the New England Journal of Medicine in 2021, remains the landmark study for injectable semaglutide in adults with obesity. Over 68 weeks, participants receiving semaglutide 2.4mg once weekly lost an average of 14.9% of their body weight compared to 2.4% in the placebo group. (Wilding JPH et al., NEJM 2021. PMID: 33567185)

More than 86% of participants lost at least 5% of their body weight. Around one-third lost 20% or more.

These results are for the branded Wegovy formulation. Compounded injectable semaglutide has not been separately evaluated in large-scale randomized controlled trials.

Oral Semaglutide for Weight Loss

The OASIS-1 trial, published in The Lancet in 2023, evaluated oral semaglutide 50 mg (a dose higher than the diabetes-approved Rybelsus) for weight management in adults with overweight or obesity without diabetes (Knop FK et al., *Lancet* 2023; PMID: 37385278). At 68 weeks, participants in the oral semaglutide group lost an average of 15.1% of their body weight compared to 2.4% with placebo — broadly in the same range as the injectable STEP 1 result (14.9%), though trial populations and protocols differ and the two trials were not head-to-head.

Subsequent OASIS program trials evaluated a 25 mg dose. Based on this research, the FDA approved the Wegovy pill (oral semaglutide 25 mg once daily) on December 22, 2025 for chronic weight management — the first oral GLP-1 approved for that indication.

For patients who strongly prefer not to inject, the oral formulation at higher doses appears to produce weight-loss outcomes in a similar range to the injectable form. The injectable form has a longer real-world track record at the 2.4 mg dose and a more established safety profile across a broader population. Cross-trial comparisons should be interpreted cautiously.

Individual results vary based on adherence, starting weight, diet, exercise, and metabolic factors. These study figures do not represent guaranteed outcomes.

---

The Fasting Requirement for Oral Semaglutide

This is a critical point that catches many patients off guard: oral semaglutide must be taken under strict fasting conditions.

To absorb properly, you must take oral semaglutide:

• First thing in the morning
• With no more than 4 ounces (half a glass) of plain water
• At least 30 minutes before eating, drinking anything else, or taking other medications

Missing this fasting window significantly reduces how much semaglutide actually enters your bloodstream. Eating or drinking within that window can drop absorption by 50% or more.

For many people, this daily fasting protocol is manageable. For others - particularly those with early morning coffee routines, shift workers, or people who take other medications in the morning - it can be a real barrier to consistent adherence.

Injectable semaglutide has no such restriction. You inject once weekly with no food or timing requirements.

---

Who Might Prefer Oral Semaglutide?

Oral semaglutide is worth discussing with your provider if you:

• Have a strong preference to avoid needles
• Have a consistent morning routine that allows for the 30-minute fasting window
• Are already comfortable with daily medication habits (similar to taking a daily oral contraceptive or thyroid medication)
• Have mild needle anxiety that creates a real barrier to starting an injectable treatment

---

Who Might Prefer Injectable Semaglutide?

Injectable semaglutide is often the more practical choice if you:

• Prefer a once-weekly schedule over a daily pill
• Have a morning routine that makes fasting impractical (coffee, early medications, irregular schedules)
• Want a formulation with the longest and most extensive clinical track record
• Are comfortable with subcutaneous injections (most patients report them as minimally uncomfortable)

Many patients who had initial anxiety about injecting find the weekly auto-injector pen easy to use after the first dose. This is worth discussing with your provider rather than ruling out injections automatically.

---

What About Compounded Semaglutide Tablets?

Licensed compounding pharmacies can prepare oral semaglutide formulations based on individual prescriptions from licensed providers. These are not FDA-approved, are not equivalent to Rybelsus or oral Wegovy, and are not subject to FDA review for safety, efficacy, or quality. They are prepared specifically for an individual patient, based on a provider's clinical judgment.

Compounded oral semaglutide formulations are an option some providers include in their programs. If this is relevant to you, your provider can discuss whether a compounded oral formulation is appropriate for your specific clinical situation.

Prescriva connects you with licensed healthcare providers who evaluate whether compounded weight management medications are right for you. Your medication, if prescribed, is prepared by a licensed compounding pharmacy based on your provider's prescription.

---

Questions to Ask Your Provider

When discussing oral vs injectable semaglutide with a provider, consider asking:

1. Given my health history, is one formulation more appropriate than the other?
2. Am I a good candidate for the oral fasting protocol?
3. What dosing schedule do you recommend, and how long before I see results?
4. What should I do if I miss a dose?
5. Are there any medications I take that could interact with oral semaglutide?

Your provider's clinical assessment matters more than general comparisons. What works well for most people may not be the right fit for your specific situation.

---

Frequently Asked Questions

Is oral semaglutide as effective as injectable semaglutide?

Clinical trial data suggests that higher-dose oral semaglutide (50mg) can produce weight loss outcomes in a similar range to injectable semaglutide 2.4mg. OASIS-1 reported approximately 15.1% mean body weight reduction at 68 weeks for oral semaglutide 50 mg, and STEP 1 reported approximately 14.9% for injectable semaglutide 2.4 mg. These trials were not head-to-head and used different patient populations and protocols, so direct cross-trial comparisons should be interpreted cautiously. Your individual results will depend on adherence, diet, exercise, and other personal health factors.

Can I switch from injections to tablets?

Switching formulations is something to discuss with your provider. They will consider your current dose, how well you are tolerating treatment, and whether an oral formulation makes sense for your situation.

Is compounded oral semaglutide available?

Licensed compounding pharmacies may prepare oral semaglutide formulations. These are not FDA-approved. If you are interested in this option, discuss it with a licensed provider who can evaluate your eligibility and, if appropriate, issue a prescription.

Does oral semaglutide cause the same side effects as injections?

Both forms share similar GI side effects (nausea, diarrhea, constipation) because they act on the same receptors. The oral form may cause more GI symptoms in some patients due to the SNAC absorption enhancer. Both formulations use a gradual dose escalation to minimize side effects.

Is Rybelsus approved for weight loss?

No. Rybelsus (oral semaglutide 3 mg, 7 mg, and 14 mg) is FDA-approved specifically for type 2 diabetes management, not weight management. The Wegovy pill (oral semaglutide 25 mg), a higher-dose formulation specifically developed for obesity treatment, received FDA approval on December 22, 2025, with commercial launch in early January 2026.

---

Ready to Explore Your Options?

Understanding the difference between oral and injectable GLP-1 medications is just one part of the process. A licensed provider can evaluate your full health picture and help you determine which approach - and which formulation - makes the most sense for you.

Ready to explore your options? Check your eligibility at Prescriva and speak with a licensed provider who can walk you through both injectable and oral treatment paths.

---

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *New England Journal of Medicine*. 2021;384:989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Knop FK, et al. "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial." *The Lancet.* 2023;402(10403):705-719. [PMID: 37385278](https://pubmed.ncbi.nlm.nih.gov/37385278/)
3. U.S. Food and Drug Administration. "[FDA approves first oral GLP-1 treatment for type 2 diabetes](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes)." FDA News Release. September 20, 2019.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide (oral or injectable) is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Rybelsus, Ozempic, or Wegovy).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.